KW-5092, a novel gastroprokinetic agent, reverses the norepinephrine-induced decline of the gastric mucosal blood flow in rats.
We examined the effects of KW-5092 ((1-[2-[[[5-(piperidinomethyl)-2-furanyl]methyl]-amino]ethyl]- 2-imidazolidinylidene) propanedinitrile fumarate), a novel gastroprokinetic agent, on gastric mucosal blood flow (GMBF) in anesthetized rats. Intravenous infusion of KW-5092 (0.1 mg/kg/min for 30 min), which did not affect the basal GMBF, reversed the norepinephrine (1 microgram/kg/min, i.v. infusion for 30 min)-induced decline of GMBF in the corpus and the antrum. The improvement by KW-5092 of the GMBF was abolished by atropine (0.1 mg/kg/min, i.v. infusion for 30 min). These results suggest that KW-5092, via cholinergic activation, could counteract the decline of GMBF induced by adrenergic activation.
Kishibayashi
N
N
Department of Pharmacology, Kyowa Hakko Kogyo Co., Ltd., Shizuoka, Japan.
Karasawa
A
A
D000818:Animals; D001783:Blood Flow Velocity / Q000187:drug effects*; D005753:Gastric Mucosa / Q000187:drug effects*; D005765:Gastrointestinal Agents / Q000494:pharmacology*; D007093:Imidazoles / Q000494:pharmacology*; D008297:Male; D009570:Nitriles / Q000494:pharmacology*; D009638:Norepinephrine / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors
D005765:Gastrointestinal Agents; D007093:Imidazoles; D009570:Nitriles; C081341:KW 5092; D009638:Norepinephrine